Purpose {#S0001}
=======

Investigations into the dosimetric and radiobiological effects of plaque size selection, radionuclide type, prescription dose and plaque positioning for eye plaque brachytherapy have been performed \[[@CIT0001]--[@CIT0005]\]. Recommendations exist regarding pre-operative quality assurance (QA) procedures such as source strength verification using a well chamber with a NIST-traceable calibration \[[@CIT0006], [@CIT0007]\]. Recent efforts have also been made to incorporate material and anatomical heterogeneities into treatment planning for eye plaque brachytherapy \[[@CIT0007]--[@CIT0011]\]. Yet despite these advancements, it remains primitive compared to other conventional brachytherapy modalities such as intracavitary accelerated partial breast irradiation and vaginal cylinder high dose-rate ^192^Ir brachytherapy \[[@CIT0012]\], particularly with regards to conformity of the delivered dose to the clinical tumor volume. Additionally, though professional society recommendations are only available for COMS-plaques \[[@CIT0001], [@CIT0006]\], non-COMS eye plaque brachytherapy is practiced in many institutions worldwide \[[@CIT0013]--[@CIT0016]\]. Standardized and accurate dose calculation methods are required to facilitate evaluation of these dissimilar treatment devices.

The current prescriptive paradigm for eye plaque brachytherapy simply recommends that the prescription isodose line pass through the tumor apex and cover the entire tumor \[[@CIT0001]\]. As no guidelines exist regarding tumor dose uniformity, typical COMS plaque tumor basal doses are a factor of 2.5-8 times higher than those at the apex \[[@CIT0009]\]. For non-COMS plaques, tumor basal doses may be as much as 70 times higher than the prescription dose \[[@CIT0017]\]. Such he-terogeneous dose distributions risk toxicities in the proximal retina and sclera and inhibit identification of an angiogenic choroidal tumor base or a neoplastic advancing apical nevus as the true clinical target for eye plaque brachytherapy. Without knowledge of such a target, physical prescription dose de-escalation studies for eye plaque brachytherapy are unguided, and thus the same prescription dose has persisted for over the last 25 years, in contrast to other ocular melanoma treatment modalities such as stereotactic radiosurgery \[[@CIT0018]\]. A dosimetric advantage of the COMS-plaques is the Silastic seed-carrier insert, which provides a reproducible source arrangement and dosimetric attenuation through tangential angles. To our knowledge, no research exists on the dosimetric effects of optimization methods such as varied intra-plaque source strengths and radionuclide choices or the clinical feasibilities therein for COMS-style eye plaque brachytherapy. The absence of such data restricts further coordinated refinement or dosimetric optimization of COMS-plaque eye brachytherapy towards achieving more conformal and uniform tumor dose distributions with less dose to critical structures. This study endeavors to explore these aspects.

Material and methods {#S0002}
====================

Rings {#S20003}
-----

The TG-43 hybrid technique \[[@CIT0019]\] currently requires a cylindrically-symmetric dose distribution; this is due to treatment planning system (TPS) limitations with respect to TG-43 parameter \[[@CIT0020]\] dataset entry. As such, it is outside the scope of this current investigation to explore the dosimetric effects of varying individual sources within a particular COMS-plaque. It is, however, possible to parse each COMS-plaque into constituent rings of sources, as the Silastic seed-carrier arranges sources about concentric circles of different radii ([Fig. 1](#F0001){ref-type="fig"}). In this manner, each COMS-plaque dose distribution may be considered as the superposition of these rings. The dosimetric influence of altering the source strength and radionuclide of component rings can then be explored. In this manuscript, the rings are enumerated in ascending order from the center of the plaque outward for reference: the 16 mm plaque in [Fig. 1](#F0001){ref-type="fig"} thus consists of ring \#1 (innermost, 2 sources), ring \#2 (middle, 4 sources) and ring \#3 (outermost, 7 sources).

![Example of a 16 mm standard COMS-style eye plaque as viewed from the concave side of the Silastic insert (light grey). The plaque central-axis Z points out of the page (i.e., into the globe). The thirteen sources are designated by rectangles (dark grey), and the Modulay backing with six suture lugs (yellow) are also shown. Three constituent concentric rings of brachytherapy sources are shown (green). Figure adopted from Chiu-Tsao *et al*. \[[@CIT0007]\]](JCB-4-19363-g001){#F0001}

Following the methodology proposed above, the MCNP5 Monte Carlo (MC) radiation transport code \[[@CIT0021]\] was used to simulate dose distributions for 14, 16 and 18 mm diameter COMS eye plaques with material compositions and reference geometry identical to those employed previously \[[@CIT0005], [@CIT0009]\]. These plaque sizes were selected to investigate a range of customization capabilities afforded by their distinct numbers of rings (three in the 16 mm plaque, four in the 14 mm plaque and five in the 18 mm plaque). The plaques were populated with each of three distinct low-energy brachytherapy sources: ^103^Pd (model 200, Theragenics, Corp.^®^), ^125^I (model 6711, GE HealthCare, Inc.^®^) and ^131^Cs (model CS-1 Rev2, IsoRay Medical, Inc.^®^). Source design specifications, absorbed dose determination methods and tally geometry were identical to those developed in Gagne *et al*. \[[@CIT0005]\]. For the three radionuclides, each constituent ring of the three fully-loaded COMS plaques was activated to determine its contribution to the total dose distribution while accounting for the heterogeneous dosimetric influences of inter-seed attenuation and scatter. The dosimetric influence of replacing inactive seeds with air or water was also investigated for the range of plaques and radionuclides in this study to anticipate the possibility that the optimal COMS ring weighting for a particular tumor could involve the removal of one or more rings of seeds.

In a manner similar to Rivard *et al*. \[[@CIT0019]\], a unique virtual source position and virtual set of brachytherapy dosimetry parameters was then ascribed to each ring. These brachytherapy dosimetry parameters were based on the AAPM TG-43 report formalism \[[@CIT0020]\], and were formatted for Pinnacle^3^ TPS (Philips Medical Systems, Cleveland, OH) entry with a grid size of 0.2 mm. Such virtual ring sources were used to investigate the dosimetric advantages of using distinct ring weightings with a single radionuclide or with intra-plaque radionuclide rings versus uniformly-loaded single-radionuclide COMS plaques.

Ellipsoidal tumors {#S20004}
------------------

Three clinically representative tumors (dome-shaped ellipsoids) with apical heights of 4, 5, and 6 mm, basal diameters of 9, 11, and 13 mm, and volumes of 144, 253, and 399 mm^3^ were contoured for the 14, 16, and 18 mm COMS plaques, respectively. A MATLAB program (MathWorks, Natick, MA^®^) was developed to generate tumor dose distributions for all possible ring weighting and radionuclide permutations for a given plaque size and source strength resolution. For example, with three radionuclides (^103^Pd, ^125^I, and ^131^Cs) for each of the three rings of a 16 mm plaque, there are a total of 3^3^ = 27 possible combinations of radionuclide rings; this number scales exponentially with increased source strength resolution. Tumor dose distributions were generated in this study from \> 10^8^ permutations of ring weightings and radionuclides for a given apical prescription dose. The total plaque heterogeneity-corrected physical prescription dose from all ring combinations for the three tumors was set to 75 Gy in agreement with the uniformly-loaded ^125^I plaque results of Melhus and Rivard \[[@CIT0009]\] for equivalent prescription depths as considered in this study. This prescription dose is lower than the nominal 85 Gy -- which assumes a homogeneous water calculation environment -- to account primarily for the Modulay plaque, Silastic seed-guide insert, and interseed attenuation effects. ^125^I was selected as the reference radionuclide for comparison due to its use in the COMS protocol.

Unified dosimetry index analysis {#S20005}
--------------------------------

These ~TUMOR~ *DVH*s were evaluated using a brachytherapy-specific adaptation of the unified dosimetry index (*UDI*) of Akpati *et al*. \[[@CIT0022]\]. The *UDI* is originally defined as:$$UDI = \left\{ {\prod\limits_{k = 1}^{4}{W_{k} \times \left\{ {\mid 1 - DI_{k} \mid + 0.1} \right\}}} \right\} \times 10^{4}$$

The *DI* ~K~ are indices analyzing tumor coverage (*DI* ~1~), dose conformity (*DI* ~2~), dose homogeneity (*DI* ~3~), and dose gradient (*DI* ~4~). The *UDI* thus incorporates the weighted (*W* ~k~) contributions from all four components into a single metric that scores the overall deviation of a treatment plan from an 'ideal' plan with *UDI* equal to unity.

Akpati *et al*. define *DI* ~3~, the homogeneity index, as the ratio of the maximum dose at any point 2 mm beyond the PTV to the prescription dose. However, in COMS brachytherapy with the eye plaque sutured directly over the tumor, a more relevant investigation of tumor dose homogeneity would consider points most proximal to the plaque surface, such as at the tumor base. Though alternate homogeneity indices which incorporate volumetric considerations of the target have been investigated \[[@CIT0023], [@CIT0024]\], our definition of *DI* ~3~ in this study preserved the point-dose-ratio nature of the original from Akpati *et al*. Moreover, since a fixed apical prescription point and appropriate tumor margin ensure excellent tumor coverage, the base-to-apex homogeneity of an eye plaque brachytherapy dose distribution is appropriately examined by investigating ~TUMOR~ *D* ~MAX~.

In an effort to improve clarity of the results and subsequent discussion, the symbolism employed in this study is slightly different than that of Akpati *et al*. As such, the individual *DI* ~k~ investigated were defined as:$$$$ $$$$ $$$$ and $$DI_{4} = \textit{Dose\ Gradiet\ Index} = \left\{ {\left. \mid{1 - \frac{V_{100\%}}{V_{50\%}}}\mid \right. + 0.1} \right\} \times 10,$$

In [Eqs. (2)](#FD2){ref-type="disp-formula"}-([5](#FD5){ref-type="disp-formula"}), ~TUMOR~ *V* ~100%~ is the tumor volume receiving 100% of the prescription dose (i.e., 75 Gy), ~TUMOR~ *V* is the entire tumor volume, *V* ~100%~ is the entire eye volume receiving 75 Gy and, *V* ~50%~ is the entire eye volume receiving half of the prescription dose (i.e., 37.5 Gy). Volumes attributable to the plaque itself -- the Modulay backing, Silastic insert, and radionuclide sources -- were excluded from analysis entirely.

By their construction in the above equations, each *DI* ~K~ has an 'ideal' score of unity; one thus seeks to minimize these metrics in the treatment planning process. Equal weighting factors *W* ~k~ = 1 in [Eq.(1)](#FD1){ref-type="disp-formula"} were assigned to the component metrics in this study. This prevented inflation/deflation of the absolute score, and as such the *UDI* was confined to a parameter space ≥ 1 (see [Fig. 1](#F0001){ref-type="fig"} from Akpati *et al*.), with an 'ideal' score of unity.

For the three tumor sizes, the component metrics *DI* ~K~ and overall *UDI* were calculated for each of the ~TUMOR~ *DVH*s, and compared to those of a uniformly-loaded (subscript "REF") ^125^I plaque. As will be discussed, the dose gradient of Akpati *et al*. ([Eq. (5)](#FD5){ref-type="disp-formula"}) was found to be an inappropriate metric and was excluded from the overall *UDI* calculation. Thus, the overall *UDI* calculated for each candidate and reference plaque loading was determined by:$$UDI = \left\{ {\prod\limits_{k = 1}^{3}{W_{k} \times \left\{ {\left. \mid{1 - DI_{k}}\mid \right. + 0.1} \right\}}} \right\} \times 10^{3}.$$

TPS dosimetry {#S20006}
-------------

To assess dosimetric effects to ocular organs-at-risk (OARs) versus uniformly-loaded ^125^I plaques, the three plaque loadings responsible for the most conformal (*DI* ~2,MIN~), most homogeneous (*DI* ~3,MIN~), and best overall (*UDI* ~MIN~) tumor dose distributions for each plaque size were also simulated in a Pinnacle^3^ TPS reference eye environment. This reference eye environment contained OAR contours for the ciliary body, cornea, eyelid, lacrimal gland, lens, and optic nerve, as well as dose points for the foveola and optic disc. Dose-volume histograms (DVHs) and maximum, minimum, and average doses from each plaque loading were calculated for these structures for comparison.

Gamma-index analysis {#S20007}
--------------------

The method of Yang *et al*. \[[@CIT0025]\] was employed to quantitatively compare the raw MC dose distribution data from a uniformly-loaded 16 mm plaque with the TPS dose distribution data from a summation of the plaque\'s three constituent rings using the OmniPro I\'mRT software suite (IBA Dosimetry, Bartlett, TN). Both dose distributions were calculated with (0.2 mm)^2^ dose grid resolution, were normalized to 75 Gy at a depth of 5 mm, and comprised a (50 mm)^2^ field-of-view.

Results {#S0008}
=======

Inactive seed locations {#S20009}
-----------------------

The most dramatic dosimetric effects are observed when all but the active central ^131^Cs seed of an 18 mm plaque are replaced with water (i.e., the assumption that all empty seed slots are filled with fluid upon implant). In this scenario, central axis doses are nonetheless only \< 1.5% higher and off-axis doses only \< 2.0% higher within the globe, with the maximum dose increase occurring near the scleral surface beneath the plaque edge. Assuming a 6 mm apical prescription depth of 75 Gy for this plaque, such a removal of radioactive sources leads to a total expansion of the *V* ~50%~, *V* ~100%~ and *V* ~150%~ isodose volumes of less than 24.0, 8.4, and 1.2 mm^3^, respectively. These effects were less pronounced for all other plaque sizes and radionuclide combinations considered. For instance, minimum central- and off-axis dose increases of \< 0.6% within the globe resulted from an active central ^103^Pd seed in a 14 mm plaque having all remaining slots filled with water.

Ellipsoidal tumors {#S20010}
------------------

### DI~1~, coverage

Since the 2003 ABS report \[[@CIT0001]\] recommends that dose be prescribed to the tumor apex from an approximately cylindrically-symmetric arrangement of typically uniformly-loaded sources beneath and encompassing the base of the tumor, one might assume it is rare that the prescription isodose volume covers less than 95% of the tumor volume. However, a recent study has shown that following these recommendations, COMS eye plaque tumor coverage is a sensitive function of both prescription depth and assumed plaque placement uncertainty, and that *D* ~95%~ may be as low as 68% of *D* ~Rx~ for certain lesions \[[@CIT0026]\]. Nonetheless, the present study assumes that the plaque is placed perfectly coaxial above a cylindrically-symmetric tumor; likewise the tumor dimension and plaque size combinations in the present study also ensure adequate dose volumetric coverage. Thus, it is unlikely in the present study that any combination of radionuclide rings and source strengths would provide significantly better (or worse) coverage than a uniformly-loaded ^125^I plaque with *DI* ~1,REF~ = 1.010, 1.004, and 1.000 for the 14 mm, 16 mm, and 18 mm plaques, respectively.

Also, any combination of rings whose 75 Gy isodose volume at least encompasses the tumor scores a *DI* ~1~ of unity, and thus is indistinguishably 'better' than any other such combination with respect solely to this index. As such, further evaluation of candidate rings specifically with respect to coverage was abandoned in this study. The component *DI* ~1~ scores were nonetheless calculated and incorporated into the analysis of overall *UDI* for each ring combination as shown in [Eq. (6)](#FD6){ref-type="disp-formula"}.

### DI~2~, conformity

For the 14 mm plaque, the most conformal tumor dose distribution ([Fig. 2](#F0002){ref-type="fig"}) had a *DI* ~2,MIN~ = 6.2 versus a *DI* ~2,REF~ = 22.1 for the reference plaque, and was achieved by concentrating \> 99% of the total source strength in the center ^103^Pd source. This improved conformity came at the expense of tumor dose homogeneity, resulting in a *DI* ~3~ = 50.4 vs. *DI* ~3,REF~ = 18.6; ~TUMOR~ *D* ~MAX~ was also more than twice that of the reference 14 mm plaque.

![Ellipsoidal tumor cross-sectional views of the most conformal (*DI* ~*2*,*MIN*~), most homogeneous (*DI* ~*3,MIN*~) and best overall (*UDI* ~*MIN*~) dose distributions as compared to uniformly-loaded ^125^I (*UDI* ~*REF*~) for the 14 mm, 16 mm and 18 mm plaques. The radionuclide composition ("Pd" = ^103^Pd, "I" = ^125^I, "Cs" = ^131^Cs) and total source strength in U (parenthesized) of each constituent ring assuming a 7 day implant duration are provided at the top of the resultant dose distribution, with ring number increasing from left to right. The component metrics (*DI* ~*1*~, *DI* ~*2*~, and *DI* ~*3*~) are provided at the bottom of each respective dose distribution, with the overall *UDI* score in bold at the upper-right corner of each figure. The ellipsoidal tumors are cylindrically-symmetric about X/Y = 0.0. Tumor edges and the inner scleral edge are outlined in black. All volumes outside the inner sclera are in white at the upper-right corner of each figure](JCB-4-19363-g002){#F0002}

For the 16 mm plaque, the most conformal tumor dose distribution ([Fig. 2](#F0002){ref-type="fig"}) had a *DI* ~2,MIN~ = 5.8 versus a *DI* ~2,REF~ = 18.5 for the reference plaque, and was achieved by again concentrating \> 99% of the total source strength in the innermost pair of ^103^Pd sources. This improved conformity again compromised tumor dose homogeneity, and resulted in a *DI* ~3~ = 53.2 vs. *DI* ~3,REF~ = 19.9. ~TUMOR~ *D* ~MAX~ was more than twice that of the reference 16 mm plaque.

For the 18 mm plaque, a minimum *DI* ~2,MIN~ = 11.7 ([Fig. 2](#F0002){ref-type="fig"}) was achieved versus a *DI* ~2,REF~ = 31.6 by concentrating \> 97% of the total source strength in one central ^103^Pd source, with \< 1% of the total source strength in the ^131^Cs sources filling each of rings \#2-\#5. This most conformal dose distribution resulted in a *DI* ~3~ = 100.2 vs. *DI* ~3,REF~ = 23.8, and a ~TUMOR~ *D* ~MAX~ \> 800 Gy, more than three times higher than that for a reference 18 mm plaque.

### DI~3~, homogeneity

The most homogeneous dose distribution for the 14 mm plaque ([Fig. 2](#F0002){ref-type="fig"}) had a *DI* ~3,MIN~ = 11.8 vs. *DI* ~3,REF~ = 18.6. Rings \#1 and \#2 were filled with ^103^Pd sources comprising 5.4% and 8.2% of the total source strength, respectively and rings \#3 and \#4 were filled with ^131^Cs sources accounting for the remaining 0.1% and 86.2%, respectively. This resulted in a 23% reduction of ~TUMOR~ *D* ~MAX~ compared to a reference ^125^I plaque, albeit with compromised conformity: *DI* ~2~ = 28.1 as compared to *DI* ~2,REF~ = 22.1.

For the 16 mm plaque, the most homogeneous dose distribution ([Fig. 2](#F0002){ref-type="fig"}) gave a *DI* ~3,MIN~ = 15.1 vs. *DI* ~3,REF~ = 19.9. Ring \#1 was comprised of ^103^Pd sources having 15.2% of the total source strength and rings \#2 and \#3 filled with ^131^Cs sources accounting for the remaining 0.1% and 84.7% of the total source strength, respectively. This resulted in a 17% reduction of ~TUMOR~ *D* ~MAX~ compared to a reference ^125^I plaque, at the expense again of reduced conformity: *DI* ~2~ = 21.0 compared to *DI* ~2,REF~ = 18.5.

For the 18 mm plaque, *DI* ~3,MIN~ = 15.4 vs. *DI* ~3,REF~ = 23.8 was achieved ([Fig. 2](#F0002){ref-type="fig"}) with rings \#1, \#4, and \#5 filled with ^131^Cs sources of 0.7%, 0.9% and 82.2% of the total source strength, respectively. Rings \#2 and \#3 were filled with ^103^Pd sources of 12.9% and 3.3% of the total source strength, respectively. This loading resulted in a 25% reduction of ~TUMOR~ *D* ~MAX~ compared to a reference ^125^I plaque, though conformity was compromised with *DI* ~2~ = 37.7 compared to *DI* ~2,REF~ = 31.6.

### DI~4~, dose gradient

For the 14 mm plaque, 8 × 10^6^ permutations of radionuclide and source strength could only achieve *DI* ~4,MIN~ = 6.22 vs. *DI* ~4,REF~ = 6.82. The two other plaque sizes in this study demonstrated similar insensitivity of this metric to varied ring compositions and weightings. As discussed below, this index was found to be dosimetrically irrelevant for the purposes of the current study, and was excluded from calculation of the overall *UDI* results below.

UDI {#S20015}
---

Based on the *DI* ~4~ results above, the *UDI* in this study was a weighted product of *DI* ~1~, *DI* ~2~, and *DI* ~3~ only as expressed in [Eq. (6)](#FD6){ref-type="disp-formula"}. For the 14 mm ^125^I plaque, the lowest *UDI* ([Fig. 2](#F0002){ref-type="fig"}) was achieved using ^103^Pd in all four rings, with rings \#1-\#4 contributing 5.5%, 0.2%, 94.2% and 0.1% of the total source strength, respectively. This loading resulted in components *DI* ~1~ = 1.01, *DI* ~2~ = 15.8, and *DI* ~3~ = 18.3 for an overall *UDI* ~MIN~ = 292 vs. *UDI* ~REF~ = 414.

For the 16 mm plaque, the lowest *UDI* ([Fig. 2](#F0002){ref-type="fig"}) was achieved using ^103^Pd in all three rings with rings \#1-\#3 contributing 12.7%, 86.7% and 0.6% of the total source strength, respectively. This loading resulted in components *DI* ~1~ = 1.01, *DI* ~2~ = 11.8, and *DI* ~3~ = 24.1 for an overall *UDI* ~MIN~ = 285 vs. *UDI* ~REF~ = 371.

For the 18 mm plaque, the lowest *UDI* ([Fig. 2](#F0002){ref-type="fig"}) was achieved using ^125^I in ring \#1, ^103^Pd in rings \#2 and \#3, and ^131^Cs in rings \#4 and \#5; the rings contributed 1.7%, 5.7%, 19.1%, 2.4% and 71.1% of the total source strength, respectively. This loading resulted in components *DI* ~1~ = 1.00, *DI* ~2~ = 35.7, and *DI* ~3~ = 15.6 for an overall *UDI* ~MIN~ = 558 vs. *UDI* ~REF~ = 750.

TPS dosimetry {#S20016}
-------------

Dose distributions in the reference eye environment for the 14 mm plaque loadings described above are shown in [Figure 3](#F0003){ref-type="fig"} with resultant OAR DVHs shown in [Figure 4](#F0004){ref-type="fig"}. [Table 1](#T0001){ref-type="table"} provides OAR dose information for all three plaque sizes.

![Pinnacle3 TPS dose distributions for the most conformal (*DI* ~*2*,*MIN*~), most homogeneous (*DI* ~*3,MIN*~), best overall (*UDI* ~*MIN*~), and uniformly-loaded ^125^I (*UDI* ~*REF*~) 14 mm plaque loadings visualized on an axial (inferior/superior) cross section of a right (OD) eye at the nasal equator of the globe. OAR contours include the ciliary body (aqua), cornea (yellow), eyelid (beige), lens (red), and optic nerve (orange). Concentric circles establish the inner- and outer scleral boundaries (white), and a dose point simulates the optic disc (orange crosshair). The lacrimal gland and foveola are not pictured. Isodose lines are provided for 1, 5, 10, 30, 50, 65, 75, 85, 100, 150, 300, and 500 Gy, with the thick 75 Gy prescription isodose line in green](JCB-4-19363-g003){#F0003}

![OAR DVHs for the corresponding 14 mm plaque dose distributions from [Figure 3](#F0003){ref-type="fig"}](JCB-4-19363-g004){#F0004}

###### 

OAR dosimetric information for the most conformal (*DI* ~2~), most homogeneous (*DI* ~3~), best overall (*UDI* ~MIN~), and uniformly-loaded ^125^I (*UDI* ~REF~) 14 mm, 16 mm, and 18 mm plaque solutions positioned at the nasal equator of the globe, as shown in [Figure 3](#F0003){ref-type="fig"}. Minimum, mean, and maximum OAR doses are provided where appropriate and the reference plaque results are emboldened and italicized. Only point doses are provided for the foveola and optic disc, as these were simply dose calculation points rather than volumetric OARs. The '--' symbol for the eyelid and optic nerve indicate that these OARs had volumes outside the dose calculation grid which therefore received no physical dose. All values presented are in units Gy

                       14 mm   16 mm    18 mm                                                                                    
  -------------------- ------- -------- -------- -------- ------- -------- -------- -------- -------- -------- -------- -------- -------
  **Ciliary body**     min     1.80     5.44     2.33     4.37    2.61     6.83     3.09     5.89     3.52     9.22     8.72     7.73
  mean                 8.05    19.11    11.40    16.15    11.87   25.49    15.44    22.82    15.59    37.02    35.35    31.42    
  max                  59.23   145.11   106.13   123.10   92.05   175.99   146.18   167.14   113.22   191.93   188.67   195.91   
  **Cornea**           min     2.12     6.22     2.78     5.05    3.08     7.86     3.70     6.85     4.15     10.68    10.10    9.02
  mean                 3.96    9.22     5.27     8.14     5.76    13.05    7.04     11.68    7.66     17.67    16.85    15.45    
  max                  9.25    19.66    12.71    17.57    13.54   28.48    17.11    25.57    17.85    41.56    39.64    35.17    
  **Eyelid**           min     0.45     1.90     0.74     1.54    0.54     1.82     0.67     1.53     --       --       --       --
  mean                 3.02    6.52     3.61     5.96     4.13    8.64     4.69     7.99     5.14     10.54    10.10    9.70     
  max                  10.49   14.67    9.93     14.87    13.64   19.13    14.08    19.65    15.15    22.72    22.43    23.54    
  **Foveola**                  3.74     9.55     4.94     8.09    5.44     12.47    6.60     11.06    7.25     17.16    16.32    14.68
  **Lacrimal gland**   min     0.94     3.42     1.22     2.66    1.36     4.30     1.62     3.59     1.87     5.79     5.43     4.71
  mean                 1.50    4.75     1.95     3.81     2.17    6.01     2.59     5.16     2.94     8.14     7.67     6.78     
  max                  2.99    7.72     3.94     6.62     4.34    10.45    5.26     9.21     5.81     14.26    13.53    12.18    
  **Lens**             min     3.42     8.85     4.47     7.32    4.96     11.14    5.94     9.90     6.64     15.12    14.40    13.02
  mean                 6.82    15.34    8.97     12.98    9.90    19.35    11.95    17.59    13.11    26.48    25.42    23.25    
  max                  14.33   29.13    19.12    25.03    20.85   36.77    25.54    34.03    27.38    51.13    49.30    45.19    
  **Optic disc**               7.29     13.27    9.90     13.00   10.66    21.59    13.31    20.12    14.05    29.39    28.31    26.94
  **Optic nerve**      min     --       --       --       --      --       --       --       --       --       --       --       --
  mean                 1.42    2.91     1.61     2.69     1.87    3.72     2.06     3.47     2.16     4.33     4.15     3.97     
  max                  9.71    18.24    13.45    17.25    14.25   29.87    18.17    27.24    18.80    44.71    42.63    38.11    

Gamma-index analysis {#S20017}
--------------------

Employing the most stringent comparative criteria (i.e. a dose difference of 1%, a distance difference of 1 mm, a search distance of 1 mm, and a 5% minimum relative signal) of the OmniPro I\'mRT software, the gamma-index analysis of the full plaque MC and TPS rings dose distributions resulted in a 99.03% pass rate. These gamma-index results are shown in [Figure 5](#F0005){ref-type="fig"}.

![Gamma-index analysis of the MC full ^125^I 16 mm plaque dose distribution versus the TPS dose distribution from the sum of the three constituent 16 mm ^125^I plaque rings. Both dose distributions were normalized to 75 Gy at a depth of 5 mm. Gamma-index results, parameters, and passing rate information are provided in the right-most image](JCB-4-19363-g005){#F0005}

Discussion {#S0018}
==========

Inactive seed locations {#S20019}
-----------------------

Of the permutations of source ring removal investigated in this study, the most clinically relevant -- based on the *DI* ~2~ results ([Fig. 2](#F0002){ref-type="fig"} and [Table 1](#T0001){ref-type="table"}) above -- is perhaps the case of an activated center seed(s) with all other sources removed. The case of a single central ^131^Cs source in an 18 mm plaque somewhat unsurprisingly produces the largest of the observed dosimetric effects in this study. Firstly, this source position possesses the largest number of proximal neighbors, and is thus subject to the largest attenuation and scatter influences from the replacement of inactive surrounding high-*Z* seeds with lower-*Z* media such as air or water. Secondly, the higher energy (∼30 keV) photon emissions from ^131^Cs likewise demonstrate the most pronounced lateral dosimetric effects as compared to the lower energy emissions from ^125^I and ^103^Pd. Lastly, this scenario involves replacement of \> 95% (20 out of 21) of the plaque\'s seeds, whereas retention of any other radionuclide ring involves necessarily less substantial changes to the dosimetric environment (i.e., it intrinsically possesses more sources). Nonetheless, the results of this "worst case scenario" above indicate a negligible dosimetric effect due to the removal of inactive rings of seeds for the purpose of eye plaque brachytherapy dosimetric optimization. Similar dosimetric effects have been investigated previously and also deemed to constitute less than a 2% variation from a fully loaded plaque \[[@CIT0027]\]. This is due in part to the source configurations of the COMS plaques having been designed explicitly to prevent interseed attenuation and shadowing and also attributed to the attenuating Silastic seed carrier insert.

Ellipsoidal tumors {#S20020}
------------------

### UDI calculations

The *UDI* and component metrics of Akpati *et al*. were evaluated as applied to eye plaque brachytherapy in this study. As mentioned in the results above, tumor coverage ([Eq. (1)](#FD1){ref-type="disp-formula"}) was not a significant concern given the assumptions of the current study, as well as the tumor dimensions and plaque sizes employed herein. As such, the optimization of this specific metric using the MATLAB code returned arbitrarily many candidate solutions whose dose distributions each resulted in the tumor volume being entirely encompassed by the 75 Gy isodose volume. For instance, all plaque loadings in [Figure 2](#F0002){ref-type="fig"} provide nearly perfect coverage. These solutions are thus essentially equivalent with respect to coverage and are therefore of little interest to the reader or clinician in themselves. This metric was retained in the calculation of overall *UDI*, however, to emphasize the importance of tumor dose coverage while striving for better conformity or homogeneity.

Defined in [Eq. (3)](#FD3){ref-type="disp-formula"} as the ratio of the entire eye volume (plaque excluded) receiving 75 Gy to the tumor volume, dose conformity for eye plaque brachytherapy is necessarily reduced by the presence of 1 mm thick sclera between the plaque and the tumor. Additionally, since plaque selection incorporates a 2-3 mm margin around the tumor base for conservative coverage \[[@CIT0001]\], peripheral conformity to the tumor volume is largely absent in traditional uniformly-loaded plaques. Thus, the dosimetric flexibility provided by varied ring weightings and radionuclides resulted in the greatest improvement of this metric for all three ellipsoidal tumors. In this manner, *DI* ~2~ also became the most important component index in *UDI* calculations for an 'optimal' loading of the 14 mm and 16 mm plaques, assuming each *W* ~k~ = 1.

As shown in [Figure 3](#F0003){ref-type="fig"} and [Figure 4](#F0004){ref-type="fig"} for the 14 mm plaque, the most conformal plaque loadings resulted in the greatest OAR sparing of those considered. Minimum, average, and maximum OAR doses were also typically 2 times lower for all plaque sizes than corresponding uniformly-loaded ^125^I plaques ([Table 1](#T0001){ref-type="table"}). This critical structure sparing, however, is offset by the 2x-3x increase in the tumor base dose versus that of the reference plaques, which likewise implies higher doses to the proximal sclera. These most conformal plaque loadings each employed a single central ^103^Pd seed (or pair of seeds for the 16 mm plaque) containing \> 97% of the total source strength to deliver the requisite dose distributions. This corresponded to source strengths of 23-57 U depending on plaque size. Such high-strength sources are beyond the current production capabilities of commercial brachytherapy source manufacturers, and also pose significant challenges to clinical implementation regarding health physics and quality assurance concerns \[[@CIT0028]\].

Modification of the original *DI* ~3~ from Akpati *et al*. in favor of that considered in this study -- the ratio of the maximum and apical prescription tumor doses -- nonetheless resulted in improved tumor dose homogeneity versus the reference plaques as shown in the second column of [Figure 2](#F0002){ref-type="fig"}. It is unlikely that more homogeneous tumor dose distributions could be produced using current COMS-style brachytherapy applicators given the limited range of photon energies for the three commercially-available radionuclides considered in this study, as well as the limited number of discrete source rings per plaque. This homogeneity came largely at the expense of conformity ([Fig. 2](#F0002){ref-type="fig"}) and OAR sparing ([Figs. 3](#F0003){ref-type="fig"} and [4](#F0004){ref-type="fig"}), however, due to the high strength ^131^Cs seeds at the plaque peripheries. Though ~TUMOR~ *D* ~MAX~ was reduced by 17-25% depending on plaque size, the OAR doses in [Table 1](#T0001){ref-type="table"} were typically 1.2 times higher than those from the reference plaques.

As defined in [Eq. (5)](#FD5){ref-type="disp-formula"}, the dose gradient is a measure of the ratio of the prescription isodose volume, *V* ~100%~, to the half-prescription isodose volume, *V* ~50%~. For eye plaque brachytherapy, an ideal optimization of this index thus seeks to minimize the difference of these isodose volumes by shrinking the *V* ~50%~ more proximal to the tumor volume (sharper dose falloff), but the same mathematical effect is achieved by instead expanding the *V* ~100%~ to encompass more volume beyond the tumor while maintaining or decreasing the *V* ~50%~. The former is dosimetrically advantageous for eye plaque treatments and results in less dose to normal ocular structures adjacent to or opposite of the plaque, whereas the latter increases the volume of healthy eye receiving 75 Gy and risks increasing ocular toxicities. The three radionuclides in this study represent a relatively narrow range of average photon energies (20--30 keV) whose physical properties unfortunately prohibit significant reductions in *V* ~50%~ while maintaining a fixed apical prescription dose. The dose gradient of COMS eye plaque brachytherapy implants is thus somewhat limited in its improvement. The *DI* ~4~ solutions in this study with expanded *V* ~100%~, however, point to the hazards of simple parameter optimization methodologies and underscore the importance of guided and thoughtful algorithmic programming. Applying a significantly lower weighting *W* ~4~ to this metric while increasing the *DI* ~2~ weighting *W* ~2~ may have constrained the MATLAB program to retain solutions with both improved conformity and steeper dose gradients, thus permitting its inclusion in the overall *UDI* calculations. The decision to maintain equal weightings *W* ~K~ in this study, however, was deliberate to emphasize the ambiguities surrounding selection of a clinically 'optimal' tumor dose distribution.

The best overall (i.e., *UDI* ~MIN~) plaque loadings for the 14 mm and 16 mm plaques produced more conformal dose distributions than the corresponding uniformly-loaded ^125^I plaques, with typically 1.6 times lower average OAR doses ([Table 1](#T0001){ref-type="table"}). For the 18 mm plaque, however, the plaque loading resulting in the *UDI* ~MIN~ produced instead a more homogeneous tumor dose distribution than the reference loading, despite being less conformal. For this plaque size, the *DI* ~3~ was the dominant component metric in the overall *UDI* calculations: with a 6 mm apical prescription depth, the conformity resulting from focusing source strength solely on inner plaque rings results in higher tumor base doses which quickly sabotage the *DI* ~3~ score as seen in the first column of [Figure 2](#F0002){ref-type="fig"}. Thus, the optimal plaque loading positioned 71% of the total source strength in ^131^Cs seeds in the outermost ring. Resultant OAR doses were typically 10% higher than those for the reference 18 mm plaque.

### Gamma-index analysis

The gamma-index method for dosimetry quality analysis has been developed and widely used for IMRT patient QA to compare measured dose distributions with those generated from the treatment planning system. Application of this method directly to brachytherapy dosimetry is difficult since the clinical medical physicist does not measure brachytherapy dose distributions. Thus, an alternate application of the gamma-index method for brachytherapy dose distributions is to compare reference and planned results as investigated in Yang *et al*. \[[@CIT0025]\]. The uniformly-loaded ^125^I plaque MC results represent the reference dose distributions in this study. The methods of this study parsed these full MC plaques into their individual rings for simulation, formatted virtual source parameter datasets from these MC ring results, entered these datasets into the TPS via the TG-43 hybrid technique, and created individual TPS ring dose distributions. By comparing these resultant TPS ring dose distributions against the standard fully-loaded plaque MC results, a quantitative dosimetric analysis of the entire process is permitted. The gamma-index results for the two 16 mm ^125^I dose distributions in [Figure 5](#F0005){ref-type="fig"} demonstrate agreement within 1%, and provide the dosimetric QA necessary for clinical adaptability of this technique.

Implementation {#S20023}
--------------

The candidate plaque loadings examined in this study offering improved conformity or homogeneity nonetheless present impediments to clinical implementation due to their employment of mixed radionuclides and non-uniform source strength weightings. Melhus and Rivard \[[@CIT0009]\] provide plaque heterogeneity-corrected physical prescription doses for the range of COMS plaques yet assume the use of a single radionuclide per plaque. It is thus unclear what corrections should be applied to the ABS recommended homogeneous 85 Gy apical prescription dose for plaques containing a variety of radionuclide rings. Varied intra-plaque radionuclide rings and source strength weightings also presents challenges to traditional clinical brachytherapy QA procedures. The importance of source distinction throughout the QA process from source strength verification to loading the Silastic insert could not be overstated in these instances.

As mentioned previously, the conformity requirements of a particular tumor dose distribution may lead to high concentrations of source strength at the upper tolerances of or even outside of current brachytherapy source manufacturer capabilities. Such high-strength sources may prove prohibitively expensive if not impossible to manufacture, and would present unique clinical concerns regarding personnel shielding and brachytherapy QA as well. Additionally, source manufacturers cannot always make seeds at the desired strength due to batching practices. This will quantize the available source strengths, especially for ^125^I, and limit the potential *UDI* ~min~.

Further, minimization of *UDI* ~min~ will be limited based on practical concerns such as potential for clinical medical physicists to measure low-energy source strengths to an accuracy (*k* = 2) of about 3%.

Limitations and future directions {#S20024}
---------------------------------

Though the dosimetric effects of inactive seed removal have been investigated and found negligible for the range of radionuclides and COMS plaques in this study, the plaque heterogeneity-corrected MC ring results presented herein assume that all Silastic seed slots in the plaque are filled with brachytherapy sources, active or otherwise. Additionally, these results are specific to the model 200 (^103^Pd, Theragenics Corp.^®^), model 6711 (^125^I, Oncura/GE HealthCare Inc.^®^) and model CS-1 Rev2 (^131^Cs, IsoRay Medical Inc.^®^) sources. The relatively narrow range of lower photon energies offered by these commercially-available radionuclide sources also necessarily restricts the tumor dose homogeneity afforded by their utilization in an episcleral treatment methodology such COMS plaque brachytherapy.

The dosimetric customization demonstrated by the various plaque loadings in this study is necessarily limited by the fixed number of rings in the COMS plaque. Other plaque types with significantly greater numbers of sources \[[@CIT0029]\] or surface patch-source modeling capabilities \[[@CIT0030]\] likely provide improved customization. A further constraint in this investigation is the requirement that all brachytherapy sources within a given ring contain the same radionuclide. This limitation is due to the dosimetry parameter input requirements of current commercial TPS which confine the TG-43 hybrid technique \[[@CIT0019]\] to cylindrically-symmetric calculation geometries. Further dosimetric customization is allowed by varying individual brachytherapy source strengths and radionuclides throughout the plaque, though these aspects are outside the scope of the current study.

The *UDI* of Akpati *et al*. was modified in this study to evaluate eye plaque brachytherapy dose distributions for coverage, conformity, and homogeneity. These dosimetric characteristics were considered with equal importance in the optimization process, though this method permits unequal weighting and thus custom target prioritization and OAR sparing on a per-patient basis. The *DI* ~K~ employed in these investigations are merely a sampling of the various quantitative metrics and evaluation criteria available to the clinical medical physicist, yet no such consensus objective measures currently exist towards identifying an 'optimal' treatment specifically for eye plaque brachytherapy. Future research should investigate both the suitability and discriminatory ability of other evaluative metrics for this treatment modality.

Conclusions {#S0025}
===========

A method has been developed for COMS plaque brachytherapy to select intra-plaque ring radionuclides and source strengths on an individual, per-patient basis to deliver more conformal and more homogeneous tumor dose distributions than a uniformly-loaded ^125^I plaque. The accurate, plaque heterogeneity-corrected dosimetry employed herein supports development of a prospective clinical protocol to determine the appropriate target (e.g., tumor base, tumor apex, tumor periphery, etc.) for eye plaque brachytherapy.
